EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Dual‐Targeted Therapy in Cardiometabolic Risk: A Meta‐Analysis of Telmisartan‐Based Combinations for Hypertension and Dyslipidemia

Rabia Asim iD, Tazheen Saleh Muhammad iD, Saad Ahmed, Laiba Khurram, Bazil Azeem iD, Mata-E-Alla Doggar, Abdullah Naveed Muhammad iD, Rahul Chikatimalla, Sowjanya Kapaganti iD, Himaja Dutt Chigurupati iD, Binish Qureshi, Harigopal Sandhyavenu und 1 weitere

Clinical Cardiology · 2025-12 · 48 (12)

DOI: 10.1002/clc.70211 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Clinical Cardiology, online erschienen am 26.11.2025. Verfasst von Rabia Asim und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Shaheed Mohtarma Benazir Bhutto Lyari Medical College, Karachi, Pakistan. Hauptthemen laut MEDLINE: Telmisartan, Dyslipidemias, Hypertension, Antihypertensive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hypertension often coexists with dyslipidemia, requiring combination therapy. Telmisartan, combined with amlodipine or rosuvastatin, targets these conditions. This meta‐analysis evaluates the efficacy and safety of these combinations in adults with hypertension and dyslipidemia.

Methods

A systematic search was conducted in Cochrane Central, MEDLINE/PubMed, ClinicalTrials.gov, and ScienceDirect (as of June 2024) for randomized controlled trials (RCTs) comparing telmisartan plus amlodipine versus telmisartan plus rosuvastatin in adults (≥ 18 years) with hypertension and dyslipidemia. A random‐effects model was used with RevMan 5.4.1. The risk of bias and heterogeneity were assessed with the Cochrane Risk of Bias Tool and the I ² statistic.

Results

Three RCTs involving 320 participants were included. At 4 weeks, telmisartan + amlodipine yielded greater sSBP (sitting Systolic Blood Pressure) reduction compared to telmisartan + rosuvastatin (MD = −10.93 mmHg; 95% CI: −19.02 to −2.83; p = 0.008; I ² = 70%). sDBP (sitting Diastolic Blood Pressure) reductions were greater in the amlodipine group at 8 weeks (MD = −8.59 mmHg; 95% CI: −13.35 to −3.82; p = 0.0004; I ² = 58%). Conversely, LDL‐C reduction was favored by telmisartan + rosuvastatin, with significant effects observed at both 4 weeks (MD = 85.98 mg/dL) and 8 weeks (MD = 79.75 mg/dL). TEAE incidence did not differ significantly (RR = 1.23; 95% CI: 0.75–2.04; p = 0.41; I ² = 0%).

Conclusion

Telmisartan + amlodipine demonstrates superior antihypertensive efficacy, while telmisartan + rosuvastatin more effectively lowers LDL‐C. Safety profiles are comparable. Findings support the selection of a regimen based on individualized therapeutic goals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TelmisartanDyslipidemiasHypertensionAntihypertensive AgentsBlood PressureHumansDrug Therapy, CombinationAmlodipineRosuvastatin CalciumRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

blood pressurehyperlipidemiahypertensionrosuvastatintelmisartan

Substanzen

TelmisartanAntihypertensive AgentsAmlodipineRosuvastatin Calcium

Autor:innen und Institutionen

  • Department of Cardiology, Shaheed Mohtarma Benazir Bhutto Lyari Medical College, Karachi, Pakistan.
  • Department of Cardiology, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
  • Department of Cardiology, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, USA.
  • Division of Cardiology, Creighton University, Omaha, Nebraska, USA.
  • Division of Cardiology, East Carolina University, Greenville, North Carolina, USA.
  • Division of Cardiology, The University of Texas Health Sciences Center, San Antonio, Texas, USA.

ORCID-Profile: Rabia Asim, Tazheen Saleh Muhammad, Bazil Azeem, Abdullah Naveed Muhammad, Sowjanya Kapaganti, Himaja Dutt Chigurupati, Sivaram Neppala

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Asim, R., Muhammad, T. S., Ahmed, S., Khurram, L., Azeem, B., Doggar, M. E., Muhammad, A. N., Chikatimalla, R., Kapaganti, S., Chigurupati, H. D., Qureshi, B., Sandhyavenu, H., & Neppala, S. (2025). Dual‐Targeted Therapy in Cardiometabolic Risk: A Meta‐Analysis of Telmisartan‐Based Combinations for Hypertension and Dyslipidemia. Clinical Cardiology, 48(12). https://doi.org/10.1002/clc.70211

Vancouver

Asim R, Muhammad TS, Ahmed S, Khurram L, Azeem B, Doggar ME, et al. Dual‐Targeted Therapy in Cardiometabolic Risk: A Meta‐Analysis of Telmisartan‐Based Combinations for Hypertension and Dyslipidemia. Clinical Cardiology. 2025;48(12). doi:10.1002/clc.70211

BibTeX
@article{Asim2025,
  author = {Asim, Rabia and Muhammad, Tazheen Saleh and Ahmed, Saad and Khurram, Laiba and Azeem, Bazil and Doggar, Mata-E-Alla and Muhammad, Abdullah Naveed and Chikatimalla, Rahul and Kapaganti, Sowjanya and Chigurupati, Himaja Dutt and Qureshi, Binish and Sandhyavenu, Harigopal and Neppala, Sivaram},
  title = {Dual‐Targeted Therapy in Cardiometabolic Risk: A Meta‐Analysis of Telmisartan‐Based Combinations for Hypertension and Dyslipidemia},
  journal = {Clinical Cardiology},
  year = {2025},
  volume = {48},
  number = {12},
  doi = {10.1002/clc.70211}
}
Kostenlos starten →